MicuRx Pharmaceuticals
3916 Trust Way
Hayward
California
94545
United States
Tel: 510-782-2021
Website: http://www.micurx.com/
Email: info@micurx.com
28 articles about MicuRx Pharmaceuticals
-
First Subject Enrolled in Phase 1 Study of MRX-5
11/20/2023
Recently, Shanghai MicuRx Pharmaceuticals Co., Ltd. announced that its proprietary antibiotic MRX-5, has enrolled its first subject in the first Phase I clinical trial in Australia.
-
MicuRx announces poster presentation and participation in ID Week 2023 Conference
10/11/2023
MicuRx Pharmaceuticals, Inc. announces that a poster on our preclinical product, MRX-6038, will be presented at ID Week entitled "In vitro Potency of a Leucyl-tRNA Synthetase Inhibitor, MRX-6038, Against Mycobacterium tuberculosis, Mycobacterium avium, and Mycobacterium abscessus."
-
MicuRx receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation for Contezolid and Contezolid acefosamil
9/22/2023
MicuRx Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has granted Qualified Infectious Disease Product and the Fast Track Designation under the Generating Antibiotic Incentives Now Act for contezolid tablet and contezolid acefosamil tablet and intravenous as novel new oxazolidinone antibiotics for the treatment of moderate to severe diabetic foot infection without concomitant osteomyelitis.
-
Infectious disease specialist Dr. Regis A. Vilchez is appointed CMO of MicuRx Pharmaceuticals, Inc.
2/8/2023
Shanghai MicuRx Pharmaceutical Co., Ltd. announced recently that it has appointed Regis A. Vilchez, MD, PhD, an experienced R&D biopharmaceutical executive and infectious disease expert, as Chief Medical Officer of its American subsidiary, MicuRx Pharmaceuticals, Inc.
-
China NMPA Approves MicuRx's Contezolid for Treatment of Drug-Resistant Bacterial Infection
6/3/2021
MicuRx Pharmaceutical Co., Ltd. (MicuRx), announced that China National Medical Products Administration (NMPA) has approved its new drug application for contezolid as the treatment of complicated skin and soft tissue infection.
-
MicuRx Announces CARB-X US$7.78 Million Funding for Development of MRX-8
8/13/2020
MicuRx Pharmaceuticals Inc. today announced that the global partnership Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) has committed up to US$7.78 million of nondilutive financing for a Ph
-
MicuRx Reports Positive Top-line Results of a China Phase 3 Clinical Trial for Novel Antibiotic Contezolid in Complicated Skin and Soft Tissue Infections
9/19/2019
MicuRx Pharmaceuticals, Inc., today announced positive top-line results from the pivotal Phase 3 clinical trial in China for its lead antibacterial drug candidate contezolid (MRX-I) in adult patients with complicated skin and soft tissue infection (cSSTI)
-
MicuRx Pharmaceuticals Reports Positive Top-Line Results From a US Phase 2 ABSSSI Clinical Trial of Novel Antibiotic Contezolid Acefosamil
9/9/2019
MicuRx Pharmaceuticals, Inc., today announced positive top-line results for study MRX4-201, a US Phase 2 randomized, double-blind clinical trial comparing contezolid acefosamil (MRX-4) with linezolid for the treatment of acute bacterial skin and skin structure infections (ABSSSI).
-
MicuRx Enrolls First Patient in a Phase 2 Clinical Trial in U.S. for Novel Antibiotic, Contezolid Acefosamil
11/26/2018
MicuRx Pharmaceuticals, Inc., today announced that the first patient has been enrolled in a Phase 2 clinical trial of contezolid acefosamil for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE
-
MicuRx Announces Funding from CARB-X for Innovative Polymyxin Antibiotic MRX-8
3/5/2018
MicuRx Pharmaceuticals, Inc. announced that the global partnership Combating Antibiotic Resistant Bacteria Accelerator (CARB-X) has committed up to $5.2 million of non-dilutive financing for IND enablement and subsequent Phase 1 clinical studies of MRX-8, also known as PMX-8.
-
Week in Review: China Life Science Deals Total $550M
12/11/2017
Pfizer acquired China/Asia rights for Cresemba, an antifungal drug developed by Swiss pharma Basilea, in a $226M deal.
-
MicuRx Announces Closing of ¥100M Funding
12/6/2017
Funds will support completion of the ongoing Phase 3 program for its oral antibiotic, contezolid as well as the projected Chinese NDA filing, along with other business activities in China.
-
MicuRx Pharma Initiates Phase 1 Clinical Trial In U.S. For Novel Antibiotic Agent MRX-4
11/30/2016
-
MicuRx Pharma Initiates Phase 3 Clinical Trial for MRX-I, A New Potent Oral Antibiotic Against Gram-positive Bacteria, Including MRSA
10/20/2016
-
Bay Area's MicuRx Pharma Bags $55 Million to Develop Next-Generation Antibiotic
9/26/2016
-
MicuRx Pharmaceuticals Reports Positive Top-Line Results From Phase 2 US Clinical Trial For Novel Antibiotic MRX-I
11/3/2015
-
MicuRx Pharmaceuticals Says Novel Antibiotic Passes China Phase II Test
9/1/2015
-
MicuRx Pharmaceuticals Reports Positive Top-Line Results In Phase 2 Clinical Trial For Novel Antibiotic MRX-I In Complicated Skin And Soft Tissue Infections
8/31/2015
-
MicuRx Pharmaceuticals Initiates U.S. Phase 2 Clinical Trial For Novel Antibiotic MRX-I
2/25/2015
-
MicuRx Pharmaceuticals Expands Global Clinical Trial Program For Oral Antibiotic MRX-I
12/20/2013